Potent and conditional redirected T cell killing of tumor cells using Half DVD-Ig
Authors:
Open Access
- 5 June 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 9 (1) , 121-129
Abstract
Novel biologics that redirect cytotoxic T lymphocytes (CTLs) to kill tumor cells bearing a tumor associated antigen hold great promise in the clinic. However, the ability to safely and potently target CD3 on CTL toward tumor associated antigens (TAA) expressed on tumor cells remains a challenge of both technology and biology. Herein we describe the use of a Half DVD-Ig format that can redirect CTL to kill tumor cells. Notably, Half DVD-Ig molecules that are monovalent for each specificity demonstrated reduced non-specific CTL activation and conditional CTL activation upon binding to TAA compared to intact tetravalent DVD-Ig molecules that are bivalent for each specificity, while maintaining good drug like properties and appropriate PK properties.Keywords
This publication has 29 references indexed in Scilit:
- Engineering a Monomeric Fc Domain Modality by N-Glycosylation for the Half-life Extension of BiotherapeuticsJournal of Biological Chemistry, 2013
- Challenges and approaches for the development of safer immunomodulatory biologicsNature Reviews Drug Discovery, 2013
- Soluble Monomeric IgG1 FcJournal of Biological Chemistry, 2012
- Strategies for extended serum half-life of protein therapeuticsCurrent Opinion in Biotechnology, 2011
- T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cellsProceedings of the National Academy of Sciences, 2010
- Applications of single-chain variable fragment antibodies in therapeutics and diagnosticsBiotechnology Advances, 2009
- CD3-specific antibodies: a portal to the treatment of autoimmunityNature Reviews Immunology, 2007
- CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysisMolecular Immunology, 2007
- Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic reviewToxicology, 1995
- Redirecting the Cellular Immune ResponseInternational Reviews of Immunology, 1989